Thomas William LeBlanc

Thomas William LeBlanc

Top Cited Scholar 2026
Auto-generated profile, based on publicly available information

Thomas William LeBlanc

Duke University School of Medicine, Durham, USA

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2015 in Journal of the National Comprehensive Cancer Network
Verified
Journal Article
Closed access
PDF file
ABAnn M. Berger
Ann M. Berger
KMKathi Mooney
Kathi Mooney
AAAmy Alvarez-Perez
Amy Alvarez-Perez
WBWilliam S. Breitbart
William S. Breitbart
KCKristen M. Carpenter
Kristen M. Carpenter
CSCourtney Smith
Courtney Smith
Cancer-related fatigue is defined as a distressing, persistent, subjective sense of physical, emotional, and/or cognitive tiredness or exhaustion related to cancer or cancer treatment that is not proportional to recent activity and interferes with usual functioning. It is one of the most common side effects in patients with cancer. Fatigue has been shown to be a consequence of active treatment, but it may also persist into posttreatment periods. Furthermore, difficulties in end-of-life care can be compounded by fatigue. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cancer-Related Fatigue provide guidance on screening for fatigue and recommendations for interventions based on the stage of treatment. Interventions may include education and counseling, general strategies for the management of fatigue, and specific nonpharmacologic and pharmacologic interventions. Fatigue is a frequently underreported complication in patients with cancer and, when reported, is responsible for reduced quality of life. Therefore, routine screening to identify fatigue is an important component in improving the quality of life for patients living with cancer.

1 September 2015 in JAMA Oncology
Verified
Journal Article
Closed access
PDF file
HPHolly Prigerson
Holly Prigerson
YBYuhua Bao
Yuhua Bao
MSManish A. Shah
Manish A. Shah
MPM. Elizabeth Paulk
M. Elizabeth Paulk
TLThomas W. LeBlanc
Thomas W. LeBlanc
PMPaul K. Maciejewski
Paul K. Maciejewski
Physicians have voiced concerns about the benefits of chemotherapy for patients with cancer nearing death.1-5 In 2012, an American Society of Clinical Oncology (ASCO) expert panel identified chemotherapy use among patients for whom there was no evidence of clinical value6 as the most widespread, wasteful, and unnecessary practice in oncology. Adequate patient performance status is often used as an indicator of whether the patient will be able to tolerate chemotherapy and respond to treatment. For this reason, performance status is used to gauge whether chemotherapy will offer clinical value.

1 May 2015 in JAMA Internal Medicine
Verified
Journal Article
Open access
PDF file
JKJean S. Kutner
Jean S. Kutner
PBPatrick J. Blatchford
Patrick J. Blatchford
DTDonald H. Taylor
Donald H. Taylor
CRChristine S. Ritchie
Christine S. Ritchie
JBJanet H. Bull
Janet H. Bull
AAAmy P. Abernethy
Amy P. Abernethy
Safe and effective use of medicines includes medication selection and dosing for a targeted indication, monitoring for benefits and harms, and discontinuation when appropriate. Data from clinical trials guide the initiation of long-term medication therapy for primary or secondary prevention of cardiovascular disease but rarely define the timing, safety, or risks of discontinuing the agents. As a result, the number of medications often accumulates.1,2

1 June 2019 in Journal of the National Comprehensive Cancer Network
Verified
Journal Article
Closed access
PDF file
MTMartin S. Tallman
Martin S. Tallman
EWEunice S. Wang
Eunice S. Wang
JAJessica K. Altman
Jessica K. Altman
FAFrederick R. Appelbaum
Frederick R. Appelbaum
VBVijaya Raj Bhatt
Vijaya Raj Bhatt
NONdiya Ogba
Ndiya Ogba
Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. Recent advances have resulted in an expansion of treatment options for AML, especially concerning targeted therapies and low-intensity regimens. This portion of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for AML focuses on the management of AML and provides recommendations on the workup, diagnostic evaluation and treatment options for younger (age <60 years) and older (age ≥60 years) adult patients.

22 November 2016 in JAMA
Verified
Journal Article
Open access
PDF file
AEAreej El-Jawahri
Areej El-Jawahri
TLThomas LeBlanc
Thomas LeBlanc
HVHarry VanDusen
Harry VanDusen
LTLara Traeger
Lara Traeger
JGJoseph A. Greer
Joseph A. Greer
JTJennifer S. Temel
Jennifer S. Temel
Quiz Ref ID Patients with hematologic malignancies hospitalized for hematopoietic stem cell transplantation (HCT) experience physical symptoms due to chemotherapy-induced toxic effects and early posttransplantation complications.1-4 These symptoms, along with the physical isolation patients experience during the 3- to 4-week hospitalization, can contribute to a decline in their quality of life (QOL) and mood throughout their hospital stay.4-6 Furthermore, the distress patients experience during transplantation often persists and has long-term QOL and psychological consequences, further exacerbating the morbidity of HCT.2,5,7 Despite the physical and psychological burden experienced by patients undergoing HCT, studies of interventions to improve their QOL and reduce their distress during HCT are limited.1,4,8-10 Clinicians often perceive patients’ physical and psychological symptoms during transplantation to be expected and unmodifiable.4,11 Although palliative care clinicians are increasingly asked to care for patients with solid tumors, they are infrequently consulted for patients with hematologic malignancies.12-14

1 December 2022 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
JMJun J Mao
Jun J Mao
NINofisat Ismaila
Nofisat Ismaila
TBTing Bao
Ting Bao
DBDebra Barton
Debra Barton
EBEran Ben-Arye
Eran Ben-Arye
Eduardo BrueraEduardo Bruera
Eduardo Bruera
PURPOSE: The aim of this joint guideline is to provide evidence-based recommendations to practicing physicians and other health care providers on integrative approaches to managing pain in patients with cancer. METHODS: The Society for Integrative Oncology and ASCO convened an expert panel of integrative oncology, medical oncology, radiation oncology, surgical oncology, palliative oncology, social sciences, mind-body medicine, nursing, and patient advocacy representatives. The literature search included systematic reviews, meta-analyses, and randomized controlled trials published from 1990 through 2021. Outcomes of interest included pain intensity, symptom relief, and adverse events. Expert panel members used this evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS: The literature search identified 227 relevant studies to inform the evidence base for this guideline. RECOMMENDATIONS: Among adult patients, acupuncture should be recommended for aromatase inhibitor–related joint pain. Acupuncture or reflexology or acupressure may be recommended for general cancer pain or musculoskeletal pain. Hypnosis may be recommended to patients who experience procedural pain. Massage may be recommended to patients experiencing pain during palliative or hospice care. These recommendations are based on an intermediate level of evidence, benefit outweighing risk, and with moderate strength of recommendation. The quality of evidence for other mind-body interventions or natural products for pain is either low or inconclusive. There is insufficient or inconclusive evidence to make recommendations for pediatric patients. More research is needed to better characterize the role of integrative medicine interventions in the care of patients with cancer. Additional information is available at https://integrativeonc.org/practice-guidelines/guidelines and www.asco.org/survivorship-guidelines .